In its first pay-for-delay decision, the UK's Competition and Markets Authority has fined GlaxoSmithKline PLC £37.6m ($54.4m) for alleged market abuse in striking deals to delay the launch of generic copies of its antidepressant Seroxat (paroxetine).
CMA said its decision relates to conduct between 2001 and 2004 in which GSK "agreed to make payments and other...
Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?